SARS-CoV-2 antibody characterization in emergency department, hospitalized and convalescent patients by two semi-quantitative immunoassays
Detection Principle
ImmunoAssay-Antibody
Target
IgM/IgG
Testing Method Category
Testing Method
kits
Testing Method - Additional Info
Pylon COVID-19 IgM and IgG assays :Cyclic enhanced fluorescence assay (CEFA); SARS-CoV-2 MIA: microsphere immunoassay (MIA),
Reported Performance
Sensitivity: 25% (CEFA, 0-3 dpo), 14.3 (MIA, 0-3 dpo), 21.2% (CEFA, 4-7 dpo), 25% (MIA, 4-7 dpo), 69% (CEFA, 8-14 dpo), 65% (MIA, 8-14 dpo), 93.3% (15-20 dpo), 93.3% (MIA, 15-20 dpo), 100% (CEFA, >21 dpo), 100% (MIA, >21 dpo)
Sample Size
994 samples (916 patients)
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements